1.41

Price (Eu):

Target Price (Eu): 1.80

1Q13 Results


Further Increase in NAV Thanks to Migros; GdS to Sell Psychiatry Clinics

- NAV from Eu2.63 to Eu2.72 per share thanks to Migros. The changes in DeA Capital's NAV are the result of a further increase in the fair value of Kenan/Migros to TRY22.7 per share (the market price as at 31st March 2013, the actual price is now even higher, at TRY24.7 per share), on top of FOREX gains. DeA Capital closed with consolidated net debt of Eu121mn, slightly up QoQ, and a consolidated bottom line of Eu3mn. Under IAS1, the group's net result stood at Eu21.7mn thanks to the increased value of Migros.
- Générale de Santé (31% of pro-forma NAV, 14% of our valuation). GdS announced its intention to start the process for the sale of its psychiatric clinics (around Eu180mn of revenues and Eu21-22mn in EBITDA per year). Based on the multiples of recent transactions (10-11x EV/EBITDA) the cash-in could exceed Eu200mn. We believe the proceeds from any sales would be used to reduce GDS's debt load and possibly help narrow the valuation gap vs. peers (5.3x - 5.6x 2013/14 EBITDA, a hefty discount to peers, which are trading at 9x and 8x respectively). GDS's 1Q13 results were broadly in line with this year's guidance, which was reiterated, with substantially flat YoY EBITDA to be achieved thanks to cost cutting. Net debt was flattish at Eu773mn.
- Migros (30% of pro-forma NAV, 41% of our valuation). Migros reported 1Q13 revenues of TRY1,591mn, +10.4% YoY adjusted for the calendar effect. EBITDA was in line with our estimate at TRY105mn, a 6.6% margin despite the opening of 41 stores (the company now has 907). Net profit came in at TRY34.9mn. Guidance confirmed "double-digit growth" in revenues and an EBITDA margin of 6-6.5%. According to the press, several options are on the table for Migros, such as a merger with Carrefour Sabanci or an outright sale to WalMart
- AAM: IDeA FIMIT (34% of NAV and 25% of our valuation; Eu9.4bn of AuM): IDeA Fimit reported Eu16.5mn in commissions and a Eu1mn net income after PPA, beating our estimates. It had Eu9.4bn in AuM. IDEA AI (8% of NAV, 8% of our valuation; flattish AuM of Eu1.2bn): commissions came to Eu2.9mn and net income hit Eu1mn. All in all, including property management, AAM contributes close to Eu90mn in sales and Eu19-20mn of net income to the group, before PPA.
- We reiterate our positive recommendation and target price of Eu1.80. The main short-term catalyst for a re-rating is linked to the potential exit from Migros in 2013 (the subsidiary is now trading at TRY24.7), which could potentially wipe out debt and lead to the distribution of up to Eu100mn in dividends, or Eu0.36/share. Also, the sale of the GDS's psychiatry clinics could offset its weak fundamental newsflow and close the valuation gap to peers. Finally, in 2014 we also envisage potential changes at GDS, thanks to the expiry of some clauses of the shareholders' agreement, enabling DeA Capital to ask for a whole or partial exit through the market, as well as to the group's refinancing (see also our 11/3/13 report).

Key Figures	2011A	2012A	2013E	2014E	2015E
EBIT (Eu mn)	(8)	5	5	10	18
Net profit (Eu mn)	-44	-26	-8	-8	-4
EPS - New (Eu)	-0.110	-0.048	0.004	0.006	0.018
EPS - Old (Eu)	-0.110	-0.048	-0.015	-0.005	0.007
DPS (Eu)	0.000	0.000	0.000	0.000	0.000
NAVPS (Eu)	2.182	2.358	2.331	2.305	2.292
Ratios & Multiples	2011A	2012A	2013E	2014E	2015E
P/E	nm	nm	nm	nm	79.2
Div. Yield	0.0%	0.0%	0.0%	0.0%	0.0%
P/NAVPS	0.6	0.6	0.6	0.6	0.6
ROCE					

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein, and of any of its parts, is strictly prohibited. None of the contents of this document may be shared with third parties without Company authorization.

DEA CAPITAL - 12m Performance



RATING: Unchanged		
TARGET PRICE (Eu): Ui	nchanged	
Change in EPS est:	2013E	2014E
	-124.6% -	203.0%

STOCK DATA

Net Debt (Fu mn):

NAV (Eu mn)

SIOCK DAIA			
Reuters code:			DEA.MI
Bloomberg cod	e:		DEA IM
Performance	1m	3m	12m
Absolute	10.1%	1.6%	7.4%
Relative	-1.4%	-5.7%	-22.4%
12 months H/L:		1.	.48/1.17
SHAREHOLDER D	ATA		
No. of Ord. shar	es (mn):		307

Shareholder data	
No. of Ord. shares (mn):	307
Total No. of shares (mn):	307
Mkt Cap Ord (Eu mn):	434
Total Mkt Cap (Eu mn):	434
Mkt Float - ord (Eu mn):	146
Mkt Float (in %):	33.7%
Main shareholder:	
De Agostini	58.3%
BALANCE SHEET DATA	2013
Book value (Eu mn):	715
BVPS (Eu):	2.33
P/BV:	0.6

119

715



A CAPITAL - KEY FIGURES		2011A	2012A	2013E	2014E	2015E
	Fiscal year end	31/12/2011	31/12/2012	31/12/2013	31/12/2014	31/12/2015
PROFIT & LOSS (Eu mn)	Sales	58	82	85	88	93
	EBITDA	(8)	5	5	10	18
	EBIT	(8)	5	5	10	18
	Financial income (charges)	(3)	(7)	(7)	(7)	(7)
	Associates & Others	(56)	(18)	(1)	(1)	0
	Pre-tax profit (loss)	(42)	(20)	(3)	3	12
	Taxes	(4)	2	(5)	(6)	(8)
	Tax rate (%)	-9.1%	8.2%	-190.2%	241.8%	69.3%
	Minorities & discontinue activities	2	(8)	(1)	(4)	(8)
	Net profit	-44	-26	-8	-8	-4
	Total extraordinary items					
	Ebitda excl. extraordinary items	(8)	5	5	10	18
	Ebit excl. extraordinary items	(= ·)	(. = \	_	_	_
	Net profit restated	(34)	(15)	1	2	5
PER SHARE DATA (Eu)	Total shares out (mn) - average fd	307	307	307	307	307
	EPS stated fd	-0.142	-0.086	-0.028	-0.026	-0.013
	EPS restated fd	-0.110	-0.048	0.004	0.006	0.018
	BVPS fd	2.182	2.358	2.331	2.305	2.292
	NAVPS fd	2.182	2.358	2.331	2.305	2.292
	Dividend per share (ord)	0.000	0.000	0.000	0.000	0.000
	Dividend pay out ratio (%)	0.0%	0.0%	0.0%	0.0%	0.0%
CASH FLOW (Eu mn)	Change in NWC	0	0	0	0	0
	Capital expenditure	0	0	0	0	0
	Other cash items	0	0	0	0	0
	Free cash flow (FCF)		0		0	
	Acquisitions, divestments & other					
	Dividend	(00)	(04)		,	10
	Change in Net Financial Position	(82)	(21)	4	6	12
BALANCE SHEET (Eu mn)	Total fixed assets	770	846	833	818	802
	Net working capital	1	1	1	1	1
	Long term liabilities	770	0.47			
	Net capital employed	772	847	834	820	803
	Net financial position	103	124	119	113	101
	Group equity	669 0	723	715	707	703
	Minorities		0	0	0	0
	Net equity	669	723	715	707	703
NAV DATA (Eu mn)	Properties and other assets - Book value					
	Properties and other assets - Market value	//0	700	715	707	702
	NAV	669	723	715	707	703
RATIOS(%)	EBITDA margin*	nm	6.5%	5.6%	11.5%	19.3%
	EBIT margin*					
	Gearing - Debt/equity	-15.3%	-17.1%	-16.7%	-16.0%	-14.3%
	Interest cover on EBIT	nm	0.8	0.7	1.5	2.7
	Debt/Ebitda	13.47	nm	nm	nm	nm
	Capex as % sales	0.0%	0.0%	0.0%	0.0%	0.0%
	ROCE*					
ODOMETI DATES (S.)	ROE*	E3 U0/	A1 10/	4 20/	2 40/	E 40/
GROWTH RATES (%)	Sales EBITDA*	53.0%	41.1%	4.2% -10.9%	3.4%	5.6% 76.6%
	EBIT*	nm	nm	-10.9%	113.0%	76.6%
	Net profit	nm	nm	nm	nm	nm
	EPS restated				nm 50.0%	nm 220.9%
	Li 3 lestaten	nm	nm	nm	30.0%	220.7%

^{*} Excluding extraordinary items

Source: Intermonte SIM estimates

Consolidated Results

DEACAPITAL Group P&L (Eu m)	1Q12 A	2Q12 A	3Q12 A	4Q12 A	2,012	1Q13 A	2,013
Private equity	0.6	0.6	(21.0)	(10.3)	(30.1)	2.3	(6.0)
Alternative AM	2.7	6.0	5.0	2.9	16.6	3.8	11.5
Holding COSTS/fin charges	(4.7)	(2.4)	(5.5)	(0.1)	(12.7)	(3.4)	(13.9)
Net profit	(0.9)	2.2	(20.0)	(7.6)	(26.3)	2.7	(8.5)
NFP	(104.7)	(113.1)	(110.6)	(123.6)	(123.6)	(121.9)	(119.2)
Equity	700.3	728.3	708.3	744.2	744.2	746.9	
p.s. (before BB)	2.51	2.62	2.59	2.63	2.63	2.72	

Source: Company Data and Intermonte SIM

DeA Capital closed with a consolidated net debt of Eu122mn, slightly down QoQ, and a positive consolidated bottom line of Eu2.7mn.

Group results under IAS1 stood at Eu21.7mn, thanks to a further increase in the valuation of Migros to TRY22.7p.s as at 31st March. It is now trading even higher, at close to TRY24p.s.

On a full year basis GDS's contribution should lead to a small negative result from private equity, while the positive contribution of Alternative AAM should be enough to cover holding costs and financial charges, before the PPA charge of around Eu9.6mn.

Changes in NAV are also mainly the result of a further increase in the fair value of Kenan/ Migros to TRY22.70 (the market price at the end of March), and to a lesser extent the increase in the value of +IDeA's FoF and Colnv funds. Migros is now trading even higher, at close to TRY24p.s., potentially leading to a further increase in reported NAV (to around Eu2.79p.s). Currently, DeA Capital is trading at a discount of roughly 48% to its reported NAV.

Reported NAV

DeA Capital NAV at Pro-form	na Book Value as of:			31/03/2013			
Asset	Activity	Stake	Value (€ mn)	per share €	% of NAV	Valuation method	vs. OLD Value
Santè SA	Healthcare	42.9%	229.6	0.84	30.9%	Net equity 7.5x 2012 Ebitda	1.5%
Kenan (Migros)	Food Retailer	17.1%	239.8	0.88	32.2%	22.7 TRY p.s. 11.7x EV/EBITDA	7.2%
IDEA FIMIT (incl put option)	Alternative AM	61.0%	171.5	0.63	23.0%	Net equity / Fair Value 13.6 PE	1.8%
Innovation RE	Alternative AM	100.0%	5.7	0.02	0.8%	1.7x EBITDA	5.6%
IDeA Capital Funds SGR	Alternative AM	100.0%	54.7	0.20	7.4%	Net equity 12.4 PE	1.9%
Sigla&other	Consumer Credit	41.4%	14.7	0.05	2.0%	Net equity	-2.0%
IDeA Funds (FoF & Colnv)	Private Equity	n.m.	189.9	0.69	25.5%	Fair value*	5.0%
NFP and other			-161.7	-0.59	-21.7%		7.8%
Total ex treasury Shares			744	2.72	100%		2.9%
# shares (mln) net of Buy Bad	ck			273.6			

* updated quarterly by fund managers

Current price 1.41 Discount to NAV -48% Discount to investment value -40% Source: Intermonte SIM and Company Data





We reiterate our positive recommendation. The main short-term catalyst for a rerating is linked to the potential exit from Migros in 2013 (the subsidiary is now trading at TRY24.7 per share), which could potentially wipe out debt and lead to the distribution of up to Eu100mn in dividends, or Eu0.36/share. Also, the sale of GDS's psychiatry clinics, could offset its weak fundamental newsflow and close the valuation gap to peers. Finally, in 2014 we also envisage potential changes at GDS thanks to the expiry of the shareholders' agreement and the group's refinancing.

DeA Capital Valuation - Adjusted NAV

Asset	Stake	Value (€ mn)	per share €	%	Valuation method
Santè SA	42.9%	87	0.32	14.3%	DCF & Market Price @ Eu10
Kenan (Migros)	17.1%	251	0.92	41.2%	2012 Multiple and Mkt price (TRY 21.5)
Idea-FIMIT sgr	61.0%	148	0.54	24.3%	2012 MULTIPLE & NAV
Innovation RE	100.0%	5.7	0.02	0.9%	NAV
IDeA Capital Funds SGR	100.0%	55.0	0.20	9.0%	2012 MULTIPLE & NAV
Sigla	41.4%	11.6	0.04	1.9%	2012 MULTIPLE & NAV
IDeA Funds (FoF & Colnv)		189.9	0.69	31.2%	Fair value*
Cash, credits and marketable sec. 2008		-161.7	-0.59	-26.6%	
Total ex treasury Shares		609	2.23	100%	
% discount			20%		
Target price (Eu p.s.)			1.78		
Current Mkt Price			1.41		
% Upside/downside			26.3%		
# shares (mln) net of Buy Ba	ack		273.6		
* quarterly updated by fur	nd manager:	S			
Current price			1.41		
Discount to NAV			-37%		
Discount to investment val	lue		-30%		
Source: Intermonte SIM an	d Company	Data			

Operating Companies' 1Q13 Results

Générale de Santé (GDS)

(31% of pro-forma NAV, 14% of our valuation)

Générale de Santé (GDS) released operating results that were better than we expected in a quarter affected by a lack of tariff adjustments, a change in consolidation base and two fewer working days than 1Q12. Turnover fell 3.5% to Eu499mn, or by 1.9% LFL. EBITDA fell by 1.9% YoY (vs. -7.7% expected) to Eu79mn, holding up thanks to lower operating costs net of rent increases. Net profit was Eu19mn, broadly in line with our estimate. Net debt was also in line, increasing slightly to Eu773mn following a sharp reduction in 4Q12 that was obtained thanks to excellent working capital management.

The company reiterated a cautious outlook on 2Q, in line with the FY target for flat EBITDA, to be achieved thanks to cost cutting rather than tariff increases (YoY trend foreseen flat/-0.5%). Also, GDS debt must be refinanced in 2014, while the holding company's debt will need refinancing at a later date (2014-2018).

Overall, group debt/EBITDA stands at 4.7x. Santé SA's refinancing will probably be addressed when the shareholders' agreement expires. Ahead of this, GdS announced its intention to start the process for the sale of its psychiatric clinics, which generate Eu180mn of revenues and Eu21-22mn in EBITDA per year. GdS is a leader in this market, with an 18% market share; the next largest player, Orpea, has 14%. Based on the multiples of recent transactions (10-11x EV/EBITDA) the cash-in could exceed Eu200mn. We believe the proceeds from any sale would be used to reduce GDS's debt load and possibly help narrow the valuation gap vs. peers (5.3x – 5.6x 2013/14 EBITDA, a hefty discount to peers, which are trading at around 9x).

<u>Migros</u>

(32% of pro-forma NAV, 41% of our valuation)

Migros reported 1Q13 revenues of TRY1,591mn, +9.6% YoY or +10.4% YoY adjusted for the calendar effect. EBITDA was in line with our estimate at TRY105mn, a 6.6% margin despite the opening of 41 stores (the company now has 907). Net profit came in at TRY34.9mn. Below EBIT, the company benefits from a lower cost of debt.

Guidance confirmed "double-digit growth" in revenues and an EBITDA margin of 6-6.5%, with some margin dilution to be expected from further store openings (xxx expected in 2013) and aggressive pricing.

Kenan (the consortium that holds a majority stake in Migros, led by BC Partners with DeA Capital a minority shareholder) is likely to exit the investment in 2013/14. According to the press, several M&A options are on the table for Migros, such as a merger with Carrefour Sabanci or an outright sale to WalMart or others.

IDeA FIMIT

(34% of NAV and 25% of our valuation and Eu9.4bn of AuM)

IDeA Fimit reported Eu16.5mn in commissions and a Eu1mn net income, after PPA, beating our estimates. It had Eu9.4bn in AuM.

IDEA Capital Funds

(8% of NAV, 8% of our valuation and flattish AuM of Eu1.2bn),

IDeA Capital Funds generated commissions of Eu2.9mn and net income of Eu1mn. Overall, including property management, AAM contributes close to Eu90mn in sales and Eu19-20mn in net income to the group, before PPA.





Generale De Santé	è										Change	e in Est
EU mn	1Q12 A	2Q12 A	3Q12 A	4Q12 A	2,012	1Q13 E	1Q13 A	A-E%	2013 E	2014 E		2014 E
Revenues	518	497	427	487	1,929	497	499	0.5%	1,941	1,988	0%	5 <i>0</i> 9
YoY	-0.5%	-2.6%	-1.0%	-1.4%	-1.4%	-4.0%	-3.5%	0.070	0.7%	2.4%	070	07
Ebitda IFRS	80	66	29	65	240	74	79	6.3%	242	249	0%	6 0%
YoY	2.3%	0.0%	-30.8%	2.8%	-3.7%	-7.7%	-1.9%		0.8%	3.2%		
% margin	15.5%	13.2%	6.7%	13.4%	12%	15%	16%		12%	13%		
Ebit IFRS	47	34	24	30	134	48	48		117	125	0%	0%
YoY	60.7%	32.9%	826.9%	-536.8%	167.0%	-4.8%	2.8%		-12.8%	6.7%		
% margin	9.0%	6.8%	5.6%	6.1%	7%	9.6%	9.6%		6%	6%		
Net Income	19	9	15	13	56	18	19	8.6%	37	43	0%	0%
YoY	112.1%	83.3%	-242.7%	-140.8%	-296.1%	-162.4%	0.0%		-33.5%	15.1%		
NFP	-862	-847	-835	-769	-769	-773	-773	0.0%	-737	-707	0%	6 0%
MIGROS TURK												
YIL mn	1Q12 A	2Q12 A	3Q12 A	4Q12 A	2012	1Q13 E	1Q13 A	A-E%	2013 E	2014 E	2013 E	2014 E
Revenues	1,455	1,552	1,825	1,650	6,482	1,620	1,591	-1.8%	7,290	7,909	0%	6 0%
YoY	14%	13%	13%	10%	13%	13%	9%		12%	8%		
Costs	-1356	-1437	-1701	-1558	-6,052	-1,527	-1,486		-6,817	-7,395		
YoY	14%	13%	22%	11%	13%	13%	10%		13%	8%		
Ebitda IFRS	98.8	97.2	123.9	110	430	105	105	0.0%	474	514	0%	6 0%
YOY	15%	12%	14%	10%	11.1%	6%	6.3%		10.1%	8.6%		
% margin	6.8%	6.3%	6.8%	6.7%	6.6%	6.5%	6.6%		6.5%	6.5%		
D&A	-46.0	-46.5	-45.5	-44.1	-182	-42	-46		-170	-170		
YoY	n.m.	12%	71%	-7%	17.5%	-9.1%	-1001.1%		-6.6%	0.0%		
Ebit	52.8	50.7	78.4	66.019	248	68	60	-12.7%	304	344	0%	0%
YoY	14%	13%	10%	16%	7%	29%	13%		22%	13%		
% margin	4%	3%	4%	4%	4%	4%	4%		4%	4%		
Net income	61.5	72.5	-17.0	-28.9	88	19	35	83.7%	185	295	0%	6 0%
YoY			-93%	-140%	-154.0%	-69%	-43%		110.4%	59.2%		
NFP	1,587	1,475	1,401	1,476	1,476	1,450	1,443	0.0%	1,271	906	0%	6 0%
IDeA Capital Fund	s SGR											
EU mn	1Q12 A	2Q12 A	3Q12 A	4Q12 A	2012	1Q13 E	1Q13 A	A-E %	2013 E	2014 E	2013 E	2014 E
AUM	1232	1232	1238	1238	1238	1218	1232	1.1%	1179	1229	0%	
YoY	-18%	-24%	-25%	0%	0%	-1%	0%		-5%	4%		
Commissions	2.9	3.0	4.7	2.9	13.5	2.8	2.9	3.6%	12.0	12.3	0%	6 0%
YoY	-24%	-27%	-2%	-39%	-23%	-3%	0%		-11%	2%		
of which IDEA C	2.9	3.0	4.7	2.9	13.5	2.8	2.9	3.6%	12.0	12.3	0%	0%
YoY	4%	-17%	57%	-15%	18%				-11%	2%		
of which OTHER	0.0	0.0	0.0	0.0	-	-	-		-	-		
YOY		_			n.m.				n.m.	n.m.		
Net income	1.2	0.8	2.3	0.2	4.5	0.8	1.0	25.0%	4.4	4.9	0%	6 0%
* IA and WISE de-c	33% consolidate	14% d from 40	<i>53%</i>	-86%	-8%	-33%	-17%		-3%	13%		
IDeA FIMIT												
EU mn	1Q12 A	2Q12 A	3Q12 A	4Q12 A	2012	1Q13 E	1Q13 A	A-E%	2013 E	2014 E	2012 E	2014 E
AUM	9,476	9,300	9,800	9,410	9,410	9,410	9,410	0.0%	10,615	11,212	2013 E 0%	
YoY	13%	7,300 7%	11%	-1%	-1%	-1%	-1%	5.070	13%	6%	070	UK
Revenues	16.2	16.1	16.7	16.4	65.4	16.5	16.5	0.0%	68.7	71.3	0%	6 0%
YoY	15%	10.1	18%	12%	12%	2%	2%	0.070	5%	4%	070	UA
101	5.6	8.9	7.3	12.1	34	8.0	9.4	17.9%	33	38	0%	6 0%
			,		٥.					00	070	071
EBT pre PPA NETINCOME bet	5.40	n.a.	n.a.	7.0	20.8	42%	68%		22.8	26.0	0%	6 0%
EBT pre PPA			n.a. 2.7	7.0 5.1	20.8 19.4	42% 4.1	68% 4.4	7.6%	22.8 17.0	26.0 20.2	0% 0%	

PEER GROUP COMPARABLES

Générale de Santè

GDS Peer Group - Absolute Performances Minibase (Local Currency) as of 16/05/13

Stock	Price	Ссу	Mktcap	1M	3M	6M	YTD	1Y	2Y
Generale de Sante S.A.	11.00	EUR - Euro	621	11.0%	4.8%	13.6%	12.8%	23.3%	-3.9%
CURANUM AG	2.7	EUR - Euro	113	-3.3%	2.2%	30.9%	6.3%	38.3%	1.3%
Orpea S.A.	34.6	EUR - Euro	1,831	9.5%	6.2%	8.0%	3.1%	41.8%	9.7%
Rhoen-Klinikum AG	16.7	EUR - Euro	2,313	4.7%	8.8%	12.8%	9.2%	-22.1%	-0.1%
Netcare Ltd.	2,201.0	ZAR - Soutl	32,295	11.2%	11.0%	20.6%	12.0%	49.2%	55.0%
MediClin AG	4.0	EUR - Euro	189	-0.5%	-1.5%	0.1%	-4.1%	-0.1%	-5.2%
Marseille-Kliniken AG	5.2	EUR - Euro	75	-4.1%	-1.5%	35.6%	17.9%	103.9%	98.8%
Mediclinic Intl Ltd	6,865.0	ZAR - Soutl	56,771	9.0%	22.1%	41.3%	25.2%	91.4%	150.4%
Medica S.A.	13.5	EUR - Euro	647	1.4%	-4.8%	-2.8%	-10.6%	13.4%	-10.7%
Simple mean performance				3.5%	5.3%	18.3%	7.4%	39.5%	37.4%
FTSE 350 / Health Care - SS	448.8	GBP - UK F		5.3%	13.9%	25.5%	21.7%	22.2%	20.2%
STOXX 600 / Health Care - SS	579.9	EUR - Euro		6.2%	13.9%	24.0%	19.1%	34.0%	41.6%
STOXX 600	308.0	EUR - Euro		8.5%	7.2%	17.2%	10.1%	27.5%	11.1%

Source: Factset

GDS Peer Group - Multiple Comparison

Stock	Price	Ссу	Mkt cap	EV/Sales	EV/Sales	EV/Ebitda	EV/Ebitda	P/E 2013	P/E 2014	Div Yield	Div Yield	Debt/EBITDA	- 1
0.001.			тик оар	2013	2014	2013	2014	.,	.,	2013	2014	2013	
Generale de Sante S.A. Our	11.0	EUR - Euro	621	0.7	0.7	5.6	5.3	16.7	14.5	8.2%	8.2%	2.9	ŀ
Generale de Sante S.A.	11.0	EUR - Euro	621	0.7	0.6	5.4	5.1	12.8	12.2	8.2%	8.2%		1
CURANUM AG	2.7	EUR - Euro	113	0.8	0.8	6.8	5.9	12.1	8.9	0.0%	0.0%	3.8	
Orpea S.A.	34.6	EUR - Euro	1,831	2.2	2.0	12.1	10.7	16.2	14.4	2.0%	2.2%	5.9	
Rhoen-Klinikum AG	16.7	EUR - Euro	2,313	1.0	0.9	9.4	7.9	21.0	15.6	1.9%	2.5%	2.3	- (
Netcare Ltd.	2,201.0	ZAR - Soutl	32,295	1.4	1.2	9.7	8.3	16.2	14.8	2.8%	3.2%	1.2	-
MediClin AG	4.0	EUR - Euro	189	0.6	0.5	13.0	8.4	1,408.7	18.3	1.3%	1.5%	4.6	1
Marseille-Kliniken AG	5.2	EUR - Euro	75	0.6	0.6	6.4	5.8	8.1	8.0	2.1%	0.0%	2.6	-
Mediclinic Intl Ltd	6,865.0	ZAR - Soutl	56,771	2.9	2.5	13.2	11.5	21.1	18.4	1.7%	1.9%	3.8	Ŀ
Medica S.A.	13.5	EUR - Euro	647	1.4	1.3	8.3	7.4	12.3	10.4	3.7%	4.1%	3.4	П
Median	·	<u>-</u>		1.2	1.1	9.5	8.1	16.2	14.6	1.9%	2.1%	3.6	ď

Source: Intermonte SIM estimates for DEA and Factset consensus estimates for peer group





Migros

MIGROS Peer Group - Absolute	Performan	ces		Minibase (Local Currency) as of 16/05/13					
Stock	Price	Сс У	Mkt cap	1M	3M	6M	YTD	1Y	2Y
Koninklijke Ahold N.V.	12.4	EUR	13,124	4.6%	13.4%	34.2%	22.1%	32.2%	28.7%
Carrefour S.A.	23.3	EUR	16,550	13.1%	16.7%	32.8%	20.6%	71.6%	-12.1%
Casino Guichard-Perrachon	83.6	EUR	9,425	4.1%	8.8%	26.3%	16.0%	20.9%	11.2%
Etablissementen Franz Colruyt	40.2	EUR	6,768	9.9%	14.0%	12.4%	7.1%	30.2%	1.9%
Delhaize Group	49.5	EUR	5,047	17.7%	36.8%	89.2%	63.7%	61.8%	-14.9%
Metro AG	24.4	EUR	7,979	10.8%	1.0%	20.0%	16.3%	6.7%	-47.0%
Tesco PLC	373.9	GBP	30,153	1.1%	2.5%	18.7%	11.3%	19.1%	-9.5%
Costco Wholesale Corp.	111.5	USD	48,043	6.4%	9.1%	16.5%	12.9%	33.6%	34.8%
Jeronimo Martins SGPS S/A	16.8	EUR	10,569	7.2%	6.6%	23.5%	15.0%	24.7%	30.7%
Grupo Famsa S.A.B. de C.V.	22.8	MXN	9,997	4.4%	31.9%	53.6%	41.3%	91.5%	12.2%
X5 Retail Group N.V.	18.1	USD	4,918	8.6%	7.9%	6.6%	1.6%	-21.2%	-49.4%
Seventh Continent Russia		USD							
Magnit	227.5	USD	21,598	13.8%	47.7%	62.5%	47.7%	102.9%	75.0%
Organizacion Soriana S.A.B.	50.3	MXN	90,540	4.2%	6.5%	15.6%	2.0%	37.4%	33.2%
Eurocash S.A.	57.5	PLN	7,939	5.6%	18.8%	42.5%	31.6%	48.9%	93.6%
Wal-Mart de Mexico	36.3	MXN	643,517	-7.7%	-13.3%	-7.3%	-14.2%	3.6%	4.5%
Migros Ticaret A.S.	25.1	TRY	4,469	10.1%	19.8%	33.2%	16.7%	46.4%	20.4%
BIM Birlesik Magazalar A.S.	94.5	TRY	14,345	-1.6%	12.5%	18.1%	8.3%	29.5%	83.5%
Carrefoursa Carrefour Sabanci T	17.3	TRY	1,174	-5.2%	1.5%	6.8%	2.4%	10.6%	-3.9%
Simple mean performance				8.3%	12.1%	30.4%	89+%	33.4%	2.7%

Source: Factset

MIGROS Peer Group - Multiple Comparison

Migros Ticaret A.S. (consensus)

Carrefoursa Carrefour Sabanci

Migros Ticaret A.S. (our est)

BIM Birlesik Magazalar A.S.

Median

Stock	Price	Сс У	Mkt cap	EV/Sales 2013	EV/Sales 2014	EV/Ebitda 2013	EV/Ebitda 2014	P/E 2013	P/E 2014	Div Yield 2013	Div Yield 2014
Koninklijke Ahold N.V.	12.4	EUR	13,124	0.4	0.3	5.5	5.3	13.2	12.6	3.8%	4.2%
Carrefour S.A.	23.3	EUR	16,550	0.3	0.3	5.4	5.0	16.5	14.3	2.7%	3.1%
Casino Guichard-Perrachon S.A.	83.6	EUR	9,425	0.3	0.3	4.8	4.4	15.4	13.6	3.7%	4.0%
Etablissementen Franz Colruyt N	40.2	EUR	6,768	0.7	0.7	8.7	8.1	17.0	16.1	2.5%	2.6%
Delhaize Group	49.5	EUR	5,047	0.3	0.3	4.9	4.5	12.2	10.9	2.9%	3.1%
Metro AG	24.4	EUR	7,979	0.2	0.2	6.5	3.5	294.1	11.2	0.0%	4.4%
Tesco PLC	373.9	GBP	30,153	0.5	0.5	6.9	6.3	11.3	10.7	4.0%	4.3%
Costco Wholesale Corp.	111.5	USD	48,043	0.4	0.4	11.7	10.5	24.6	22.2	1.0%	1.2%
Jeronimo Martins SGPS S/A	16.8	EUR	10,569	0.9	0.8	12.7	11.0	24.1	20.3	2.1%	2.4%
Median				0.4	0.3	6.5	5.3	16.5	13.6	2.7%	3.1%
Grupo Famsa S.A.B. de C.V.	22.8	MXN	9,997	1.5	1.5	10.1	10.3	19.0	14.0	0.0%	0.0%
X5 Retail Group N.V.	18.1	USD	4,918	0.5	0.4	7.0	6.2	16.9	14.5	0.0%	0.0%
Magnit	227.5	USD	21,598	1.3	1.0	12.9	10.6	23.1	19.0	1.2%	1.5%
Organizacion Soriana S.A.B. de (50.3	MXN	90,540	0.8	0.7	11.0	9.8	21.9	19.6	0.4%	0.7%
Eurocash S.A.	57.5	PLN	7,939	0.5	0.4	14.6	12.5	23.3	19.6	1.7%	2.3%
Wal-Mart de Mexico S.A.B. de C	36.3	MXN	643,517	1.3	1.2	13.5	11.9	24.7	21.4	2.5%	2.4%

0.9

0.7

0.7

1.0

0.3

10.5

10.5

10.8

19.9

6.6

30.8

22.5

24.1

37.2

36.4 36.2

73.5

19.3

15.1

28.9

30.9

33.2

59.8

0.8%

0.0%

1.7%

0.0%

1.7%

1.1%

0.0%

2.1%

0.0%

2.1%

11.9

12.1

12.3

23.7

8 7

TRY Median 1.9 1.7 36.0 Source: Intermonte SIM estimates for DEA and Factset consensus estimates for peer group

TRY

TRY

25.1

25.1

94.5

17.3

4,469

4,469

14,345

1,174

1.0

8.0

8.0

1.2

0.3

AAM: IDeA Fimit and IDeA Capital Funds

Minibase (Local Currency) as of 16/05/13 IDeA Fimit / iDeA AI - Peer Group - Absolute Performances Stock Mkt cap 1M 1Y 2Y Ссу **Traditional Asset Managers** 88.9% 97.9% 472.9 GBP 16.2% 10.5% 43.2% 28.8% Aberdeen Asset Management 5,668 Azimut Holding S.p.A. 15.5 EUR 2,223 19.2% 21.9% 64.3% 43.0% 118.6% 100.6% F&C Asset Management PLC 90.0 GBP 506 -5.8% -12.2% -8.2% -11.9% 28.8% 12.5% Henderson Group PLC 63.9 GBP 1,968 12.5% 10.3% 61.8% 33.4% 82.4% 25.1% Rathbone Brothers PLC 1,510.0 GBP 1.1% 4.6% 20.8% 16.2% 25.0% 25.8% 696 6,875 50.9% Schroders PLC 2,545.0 GBP 17.8% 30.1% 67.7% 109.6% 53.3% **Alternative Asset Managers** Blackstone Group L.P. 22.9 USD 15,683 12.3% 18.8% 68.3% 47.1% 98.8% 36.0% 142.9% Fortress Investment Group L.L.C 7.4 USD 3,478 27.1% 16.5% 76.5% 67.7% 41.0% 126.5 19.8% 52 9% 61.0% -48 1% Man Group Plc 2.307 17.6% 76.2% **GBP** Partners Group Holding AG 240.4 CHF 6,419 2.6% 12.8% 29.6% 13.8% 50.3% 43.7% Ashmore Group PLC 428.9 GBP 3,034 7.7% 14.3% 23.1% 19.3% 29.3% 20.9% Hargreaves Lansdown PLC 1,016.0 GBP 4,819 7.1% 19.8% 35.1% 49.2% 111.4% 72.6% KKR & Co. L.P. 20.6 USD 8,066 4.4% 14.0% 47.3% 34.9% 79.2% 19.3% 10.9% Simple mean performance 10.2% 41.6% 26.8% 75.6% 52.6% STOXX 600 270.2 2.3% 15.1% 18.2% 10.5% 1.5% 5.3% EUR

Source: Factset

Source: Factset

Stock	Price	Ссу	Mkt cap	AUM	P/AUM	EV/Ebitda 2013	EV/Ebitda 2014	P/E 2013	P/E 2014	Div Yield 2013	Div Yield 2014
Traditional Asset Managers											
Aberdeen Asset Management	472.9	GBP	5,668	182.7	3.1%	11.1	8.9	16.0	13.3	3.2%	3.8%
Azimut Holding S.p.A.	15.5	EUR -	2,223	19.2	11.6%	15.2	14.3	15.1	13.4	3.5%	4.1%
F&C Asset Management PLC	90.0	GBP	506	96.8	0.5%	5.9	4.9	9.6	8.1	3.6%	4.0%
Henderson Group PLC	176.5	GBP	1,968	110.1	1.8%	10.5	9.0	14.7	13.2	4.2%	4.5%
Rathbone Brothers PLC	1,510.0	GBP	696	17.4	4.0%	10.6	9.2	17.4	14.2	3.2%	3.4%
Schroders PLC	2,545.0	GBP	6,875	195.0	3.5%	9.6	9.6	20.3	16.5	1.9%	2.2%
Alternative Asset Managers											
Blackstone Group L.P.	22.9	USD	12,732	205.0	6.2%	9.1	6.9	10.0	8.7	5.7%	6.5%
Fortress Investment Group L.L.C	7.4	USD	3,478	51.5	6.8%	17.0	12.1	10.7	9.9	5.0%	5.6%
Man Group Plc	126.5	GBP	2,307	37.8	6.1%	8.3	6.9	21.5	13.8	3.2%	5.0%
Partners Group Holding AG	240.4	CHF	6,419	37.9	16.9%	19.1	14.0	20.4	17.5	2.9%	3.5%
Ashmore Group PLC	428.9	GBP	3,034	40.1	7.6%	11.3	9.6	16.8	14.6	3.6%	4.0%
Hargreaves Lansdown PLC	1,016.0	GBP	4,819	26.3	18.3%	24.1	20.2	32.2	26.9	2.7%	3.2%
KKR & Co. L.P.	20.6	USD	8,066	66.3	12.2%	2.3	9.3	8.2	8.7	6.8%	7.1%
Median						10.6	9.1	15.5	13.4	3.4%	4.1%





DEA CAPITAL Peer Group - Absolute Performances

Stock	Price	Ссу	Mkt cap	1M	3M	6M	YTD	1Y	2Y
DEA CAPITAL	1.4	EUR	433.5	10.1%	1.6%	10.8%	5.5%	7.4%	-6.1%
31	3.5	GBP	3,358.7	6.4%	15.0%	68.0%	59.2%	92.5%	20.7%
CIR	0.9	EUR	693.8	10.9%	6.0%	6.0%	10.1%	-2.9%	-49.5%
COFIDE	0.4	EUR	320.0	11.7%	9.3%	10.7%	10.5%	-0.1%	-39.9%
DEUTSCHE BETE	18.3	EUR	249.6	0.7%	-12.2%	1.8%	-6.4%	19.9%	-6.8%
DINAMIA	6.3	EUR	101.7	21.4%	22.5%	22.5%	14.7%	124.5%	-3.6%
EURAZEO	41.8	EUR	2,664.6	6.1%	5.1%	21.2%	15.5%	36.4%	-19.4%
EXOR	24.6	EUR	6,058.8	17.2%	10.7%	31.5%	29.5%	53.2%	1.2%
GEMINA	1.5	EUR	2,162.4	10.4%	10.8%	94.2%	36.7%	133.4%	112.0%
IMMSI	0.5	EUR	167.2	14.1%	-6.6%	29.1%	9.6%	-4.3%	-40.9%
ITALMOBILIARE	16.4	EUR	616.3	9.3%	7.2%	49.7%	28.0%	31.8%	-41.7%
PREMAFIN	0.2	EUR	76.4	1.4%	-4.8%	39.6%	46.5%	6.0%	-69.3%
SVG	4.1	GBP	1,107.9	5.5%	10.8%	54.3%	41.8%	53.5%	60.5%
Mean performance				9.6%	5.8%	33.8%	23.2%	42.4%	-6.4%
Italy Fixed	17,544.0	EUR	201,658	12.9%	6.4%	18.1%	7.8%	32.1%	-19.1%

Source: FactSet

DEA Capital Peer group

	Price	YTD % \ change	Volume (EUR k)	P/NAV (reported)	Mkt Cap (EUR mln)
Deutsche Beteiligungs	18.32	-2.19%	134	0.94	263.7
Eurazeo	41.80	15.45%	3222	0.76	2254.6
GIMV	39.75	4.80%	271	0.97	921.2
Wendel	87.82	12.92%	5400	0.82	4418.6
3i (GBp)	348.20	60.31%	10780	1.22	1600.4
Candover (GBp)	383	15.36%	43	0.63	99.0
SVG Capital (GBp)	407.20	41.44%	1164	1.04	714.2
			avg.	0.96	
DeA Capital	1.42	6.27%	96	0.52	436.6
LPX Europe (-1 day)	296.6106	17.07%			
S&P/MIB	17544.76	7.81%			

Source: Bloomberg

Italian Holdings - Discount vs NAVPS

Stock	Price (Eu)	Mkt cap (Eu mn)	% Change YTD as of Now	Premium (Discount)	P/NAV
EXOR S.p.A.	24.52	6,025	29.1%	-29.9%	0.70
Compagnie Industriali Riunite S.p.A.	0.88	700	11.0%	49.0%	1.49
ASTM S.p.A	9.60	845	22.9%	-44.7%	0.55
Italmobiliare S.p.A.	16.18	534	26.4%	-61.8%	0.38
DeA Capital S.p.A.	1.41	434	5.5%	-28.6%	0.71
COFI DE Cia Finanziaria De Benedetti SF	0.45	320	10.5%	3.4%	1.03
IMMSI S.p.A.	0.49	165	8.3%	-66.7%	0.33
Camfin S.p.A.	0.83	648	51.6%	-4.7%	0.95
Average Italian Holdings		9,670	20.7%	-23.0%	0.77
Median avg. excl. see-trough NAV			17.0%	-30.4%	0.70
Median avg. excl. see-trough NAV			17.0%	-30.4%	0.70

*Note: see-trough NAV for Cofide and Camfin

Source: Intermonte SIM estimates for covered companies, FactSet consensus estimates for peer group

DEA CAPITAL - Estimates Comparison with Consensus

		2013			2014	
(Eu mn)	Intermonte	Consensus	%diff	Intermonte	Consensus	%diff
Revenues	85.4	82.5	3.6%	88.4	85.5	3.4%
Ebitda	4.8	(2.0)	-339.2%	10.2	3.0	239.8%
Net Profit	(8.5)	(14.0)	-39.6%	(7.9)	(11.0)	-28.2%
EPS	0.0	(0.0)	-113.5%	0.0	(0.0)	-131.8%
Net Debt	119.2	(3.0)	-4072.5%	112.9	(1.5)	-7627.2%

Source: Intermonte SIM estimates and Factset consensus estimates

DISCLAIMER (for more details go to http://intermonte.it/ disclosures.asp)

IMPORTANT DISCLOSURES

nformation, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte. This report is directed exclusively at market professional and other institutional investors (Institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution. The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by the Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as oblicitation to buy or sell securities.

This disclaimer is constantly updated on Intermonter's website www.intermonte.it under DISCLOSURES. Valuations and recommendations can be found in the text of the most recent

research and/or reports on the companies in question.

ANALYST CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific ecommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is

generated by intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities, and codes of conduct are alimed to ensure the impartiality of its financial analysis. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the propietary equity desk in order to prevent conflicts of interest when

Reports on all companies listed on the S&PMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period:

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period:

NEURAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period:

UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period:

SELL stock expected to underperform the market by over 25% over a 12 month period.

The stock price indicated is the reference price on the day prior to the publication of the report.

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS
Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms. As at March 31th 2013 Intermonte's Research Department covered 137 companies.

Intermonte's distribution of stock ratings is as follows:

BUY: 16,06% OUTPERFORM: 36.50% NEUTRAL: 37.22% UNDERPERFORM: 10.22%

SELL: 0.00%

SELL: 0.00%

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (26 in total) is as follows:

OUTPERFORM: 50.00% NEUTDAL : 34 629 UNDERPERFORM: 0.00%

CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

- within the last year, Intermonte SIM managed or co-managed/is managing or is co-managing (see companies indicated in bold type) an Institutional Offering and/or, managed or co-managing or is co-managing (see companies indicated in bold type) an offering with firm commitment underwriting of the securities of the following Companies: Compagnia della Ruota, Made in Italy, Sesa, TerniGreen, UniCredit.
- Intermonte SIM is Specialist and/or Corporate Broker and/or Broker in charge of the share buyback activity of the following Companies: Be, Biancamano, B&C Speakers, Carraro, Cattolica Assicurazioni, Cell Therapeutics, Credito Valtellinese, Datalogic, Dea Capital, Digital bros, El.En, Fiera Milano, Fintel Energia Group, Geffran, IGD, IGI Investimenti, Kinexia, QF Alpha Immobiliare, OF Beta Immobiliare, Firmi sul Motori, Reno de Medici, Reply, Saes Getters, Servidia, TESMEC, TBS Group, TermiGreen, Termienergia, Vittoria Assicurazioni, VR Way. Intermonte SIM SpA and its subsidiaries do not hold a stake of equal to or over 1% in any class of common equity securities of the subject company.
- o Intermonte SIM SpA acts as Financial Advisor to the following companies: Cattolica Assicurazioni

DETAILS ON STOCKS RECOMMENDATION

Stock NAME	DEA CAPITAL		
Current Recomm:	BUY	Previous Recomm:	BUY
Current Target (Eu):	1.80	Previous Target (Eu):	1.80
Current Price (Eu):	1.41	Previous Price (Eu):	1.34
Date of report:	17/05/2013	Date of last report:	11/03/2013

© Copyright 2010 by Intermonte SIM - All rights reserved
It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM ou are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONTE Sim strongly believes its research product on Italian equilities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website www.intermonte.it/mifid

